New Drugs Aim to Defeat Tumor Resistance to EGFR Inhibitors

    Emma Shtivelman, PhD

    In recent years, many people with non-small cell lung cancer (NSCLC) have been successfully treated with drugs called EGFR inhibitors. But over time, most patients develop resistance to these drugs, and the drugs stop working. Researchers are hard at work developing new drugs to help patients who can no longer be treated with EGFR inhibitors.